Published: 5 January 2021
Author(s): Dimitrios Sagris, George Ntaios, Georgios Georgiopoulos, Konstantinos Pateras, Haralampos Milionis
Issue: April 2021
Section: Letter to the Editor

Dear Editor, over the last decades lipid-modifying strategies made a pivotal change in cardiovascular prevention especially in patients with previous coronary artery disease or ischemic stroke. In these patients, low-density lipoprotein cholesterol (LDL-C) reduction is directly correlated to less future cardiovascular events, an association mediated by its effect on the burden of atherosclerosis [1]. In contrast to coronary and peripheral artery disease which are mainly caused by atherosclerosis, stroke is a heterogenous disease with distinct pathophysiological mechanisms (like atherosclerosis, atrial fibrillation (AF), patent foramen ovale, dissection, small vessel disease) that frequently overlap [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.